A rapid and durable response to cabozantinib in an osimertinib-resistant lung cancer patient with MET D1228N mutation: a case report

Osimertinib has efficacy superior to that of standard epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) for the first-line treatment of patients with EGFR-mutant advanced non-small cell lung cancer (NSCLC). However, patients treated with osimertinib eventually acquire drug re...

Descripción completa

Detalles Bibliográficos
Autores principales: Kuang, Yukun, Wang, Jiyu, Xu, Peihang, Zheng, Yifan, Bai, Lihong, Sun, Xue, Li, Zimu, Gan, Runjing, Li, Huixia, Ke, Zunfu, Tang, Kejing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8422132/
https://www.ncbi.nlm.nih.gov/pubmed/34532491
http://dx.doi.org/10.21037/atm-21-3861

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8422132/
https://www.ncbi.nlm.nih.gov/pubmed/34532491
http://dx.doi.org/10.21037/atm-21-3861

Ejemplares similares